How Platform Biotechs Are Building Drug Factories Inside the Body

Episode 20 of Biotech Business with Fexingo: Lucas and Luna explore the emerging field of 'in vivo cell engineering'—a new wave of biotech startups that aim to build drug factories inside patients' own cells. They anchor on a specific approach: lipid nanoparticle (LNP) delivery of mRNA that instructs liver cells to produce therapeutic proteins, potentially replacing frequent injections for chronic diseases. The hosts dissect a real-world case: a startup called ReCode Therapeutics, which raised $260 million to deliver mRNA to lung cells for cystic fibrosis. They compare the platform economics to traditional biologics manufacturing, debate the scalability of cell-targeting LNPs, and ask whether this is truly a paradigm shift or just a clever niche. The conversation ties to broader questions about how biotech is redefining 'manufacturing' and who will own the supply chain when the patient's body is the bioreactor. #Biotech #DrugFactory #InVivoEngineering #LNP #mRNA #ReCodeTherapeutics #CysticFibrosis #CellTherapy #GeneTherapy #PlatformBiotech #DrugDelivery #Bioreactor #ChronicDisease #Business #Technology #FexingoBusiness #BusinessPodcast #BiotechPodcast Keep every episode free: buymeacoffee.com/fexingo